Physician profile
John S Harris
NPI 1073541025
$128,762.70
in general payments reported to CMS, 2019-2025
16 companies · $57.02 in 2025
The $57.02 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69K · 2020: $6,987 · 2021: $11K · 2022: $27K · 2023: $5,471 · 2024: $9,400 · 2025: $57.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Travel and Lodging: $1,680 · Food and Beverage: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,849.00 |
| Travel and Lodging | $1,680.25 |
| Food and Beverage | $398.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $101,281.36 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $25,688.45 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $1,177.80 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $120.75 | 2023 | Camzyos |
| Boston Scientific Corporation | $114.88 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.95 | 2022 | |
| Janssen Scientific Affairs, LLC | $92.50 | 2019 | |
| Abiomed | $53.08 | 2023-2024 | Impella |
| Bracco Diagnostics INC. | $29.17 | 2025 | |
| Abbott Laboratories | $23.90 | 2022 | |
| Atricure, INC. | $23.57 | 2023 | |
| Cardiovascular Systems INC. | $18.69 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.19 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.95 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.46 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.